A detailed history of Price T Rowe Associates Inc transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 42,802 shares of PMVP stock, worth $63,774. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,802
Previous 24,944 71.59%
Holding current value
$63,774
Previous $78,000 6.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.51 - $3.12 $26,965 - $55,716
17,858 Added 71.59%
42,802 $73,000
Q3 2023

Nov 14, 2023

BUY
$6.01 - $8.93 $5,907 - $8,778
983 Added 4.1%
24,944 $154,000
Q2 2023

Aug 14, 2023

BUY
$3.94 - $6.27 $1,355 - $2,156
344 Added 1.46%
23,961 $150,000
Q1 2023

May 15, 2023

BUY
$4.77 - $9.16 $25,176 - $48,346
5,278 Added 28.78%
23,617 $113,000
Q4 2022

Feb 14, 2023

BUY
$8.17 - $12.95 $3,880 - $6,151
475 Added 2.66%
18,339 $160,000
Q3 2022

Nov 14, 2022

BUY
$11.4 - $17.18 $25,661 - $38,672
2,251 Added 14.42%
17,864 $213,000
Q2 2022

Aug 15, 2022

BUY
$9.23 - $22.43 $10,236 - $24,874
1,109 Added 7.65%
15,613 $222,000
Q1 2022

May 16, 2022

SELL
$14.86 - $23.55 $545,659 - $864,756
-36,720 Reduced 71.69%
14,504 $302,000
Q4 2021

Feb 14, 2022

SELL
$19.99 - $30.24 $2.01 Million - $3.04 Million
-100,554 Reduced 66.25%
51,224 $1.18 Million
Q3 2021

Nov 15, 2021

BUY
$26.84 - $36.58 $4.07 Million - $5.55 Million
151,778 New
151,778 $4.52 Million
Q2 2021

Aug 16, 2021

SELL
$28.01 - $36.01 $3.34 Million - $4.3 Million
-119,375 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$30.66 - $49.5 $3.66 Million - $5.91 Million
119,375 New
119,375 $3.93 Million

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $68M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.